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Abstract
Background: CXCL12/CXCR4 transactivation of epidermal growth factor family receptors in lipid raft membrane
microdomains on cell surface is thought to mediate tumor growth and subsequent development of metastatic
disease. CTCE-9908 is a known inhibitor of CXCR4. Herein, we tested the efficacy of CTCE-9908 in inhibiting prostate
cancer cell growth, invasion, and metastasis.
Methods: We used a panel of in vitro assays utilizing human prostate cancer cell lines and an in vivo orthotopic
prostate cancer model to assess the anti-tumoral activity of CTCE-9908.
Results: We demonstrated that (a) CTCE-9908 treatment resulted in no significant change in the growth of PC-3
and C4-2B cells; (b) 50 μg/ml of CTCE-9908 inhibited the invasive properties of PC-3 cells; (c) 25 mg/kg of CTCE9908 did not alter primary tumor growth but it did significantly reduce total tumor burden in the animal including
the growth of prostate and soft tissue metastases to lymph node and distant organ tissues. Histological analysis
showed that CTCE-9908 treatment resulted in tumor necrosis in primary prostate tumors and no significant change
in proliferation of tumor cells as measured by Ki-67 staining; (d) CTCE-9908 inhibited the tumor angiogenesis as
measured by CD34 positive vessels in tumors.
Conclusions: These data suggest that CXCR4 inhibition by CTCE-9908 decreases the invasion potential in vitro,
which then translated to a reduction of tumor spread with associated reduction in angiogenesis. Hence, CTCE-9908
may prove to be an efficacious novel agent to prevent and treat the spread of metastatic prostate cancer.
Keywords: CTCE-9908, CXCR4, CXCL12, Chemoinvasion and prostate cancer progression

Background
CXCR4 activation contributes to site-specific metastasis in
several types of tumors, where circulating epithelial tumor
cells express CXCR4 and common metastasis sites express
abundant ligand, and ligand/receptor interaction has been
shown to promote metastasis (reviewed in [1]). In prostate
cancer patients, CXCR4 expression is upregulated during
cancer progression [2] and aggressive cancer development
[3,4]. We and others have previously shown that the
CXCL12/CXCR4 axis plays an important role in PC cell
proliferation, migration, and invasion [2,5-13]. Furthermore,
we demonstrated that CXCL12/CXCR4 signals through the
PI3 kinase/Akt pathway to induce matrix metalloproteinase
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(MMP) expression and secretion, ultimately leading to migration and invasion of PC cells [5]. MMPs have been
shown to be involved in the metastatic growth of prostate
tumors in the bone and also appear to be activated at earlier time periods of tumor growth [14]; therefore, these data
provide a mechanistic connection between “homing” of
cancer cells to distant sites mediated by CXCL12/CXCR4
axis and followed by expression of MMPs which mediate
invasion and proliferation. Similarly, our recent data demonstrate that CXCL12 binding to CXCR4 transactivates
HER2 in PC cells to initiate chemo-invasive signaling and
promotion of bone tumor growth, suggesting that this
pathway is not only involved in initial seeding of bone metastases but also plays a key role in subsequent osseous expansion of metastases [10]. Furthermore, neutralization of
CXCR4 in prostate cancer cells with anti-CXCR4 antibodies significantly reduced metastatic burden of experimental bone metastasis [13].
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Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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Targeting CXCR4 can have dual effects on inhibiting primary tumor growth and metastasis or mono effect on inhibiting either tumor growth or metastasis. Among CXCR4
inhibitors, AMD3100 is in clinical use for leukemia [15,16],
and CTCE-9908 was granted approval by the FDA for
osteosarcoma [17] based on its potent inhibitory activity in
preclinical models of osteosarcoma [18]. AMD3100 is a
bicyclam CXCR4 inhibitor that has been shown to be effective in reducing tumor growth in glioblastoma [19] and
peritoneal metastasis in ovarian carcinoma [20]. CTCE9908 is a peptide antagonist for CXCR4 and has shown to
inhibit both primary tumor growth and metastases in
osteosarcoma [18] and breast cancer models [21]. In a prostate cancer model, CTCE-9908 caused a reduction in
tumor growth in a subcutaneous xenograft model via inhibiting angiogenesis by reducing the recruitment of proangiogenic myeloid precursor cells [22]. The current study
assessed the efficacy of CTCE-9908 in an orthotopic prostate cancer model of primary tumor growth and metastases.
The results show that CTCE-9908 is effective in reducing
total tumor burden without significantly affecting the primary tumor growth.

Methods
Cell culture

PC-3 cells were obtained from American Type Culture Collection (Manassas, VA) and cultured in RPMI 1640 (Invitrogen Life Technologies, Carlsbad, CA) supplemented
with 10% FBS and 1% Penicillin and Streptomycin. C4-2B
cells were obtained from Dr. Leeland Chung and cultured
in T media (Invitrogen Life Technologies, Carlsbad, CA)
supplemented with 10% FBS and 1% Penicillin and
Streptomycin.
Cell proliferation assay

1×104 PC-3 and C4-2B cells were seeded in a 96 well
plate; the following day, cells were treated with varying
concentrations (0–100 μg/ml) of CTCE-9908 dissolved
in sterile dH2O. After 24, 48, and 72 hours, cells were
washed with PBS and exposed to 1X dye binding solution from CyQUANT® NF cell proliferation assay kit
(Molecular Probes, Eugene, OR) for 60 min. Dye DNAbound complexes were measured at 485 nm excitation
and 530 nm emission.
Chemoinvasion assay

PC-3 cells were serum-starved for 4 hours. A total of 1.52.0 × 105 cells were seeded onto inserts in the upper chamber of trans-well culture plates (Becton Dickenson, San
Diego, CA). Prior to seeding, the inserts were pre-coated
with Matrigel. Untreated control and CTCE-9908 (1 and
50 μg/ml) pretreated PC-3 cells were seeded in Matrigel
coated inserts. CXCL12 was placed in the bottom chamber
to induce CXCR4-mediated chemoinvasion. After 24 hours,

Page 2 of 7

the upper chambers were cleaned with cotton swabs to remove non-migrated/invaded cells, and the inserts were
stained with Diff-Quik stain set (Dade Behring Inc.,
Newark, DE). The total number of migrated cells in a high
power field was counted under a microscope, and the data
presented is based on three independent experiments.
Orthotopic tumor growth and CTCE-9908 treatment

PC-3-GFP cells were grown subcutaneously as a tumor
stock. The animal experiments were performed at Anti
Cancer Inc., (San Diego, CA) in accordance with the
principles and procedures outlined in the NIH Guide for
the Care and Use of Laboratory Animals under assurance number A3873-1. Subcutaneous PC3-GFP tumor
was excised, the necrotic areas removed, and 1 mm3 of
tumor piece was implanted in the mouse ventral lobe of
the prostate [23]. Animals were treated with 25 mg/kg/
day CTCE-9908 daily, through subcutaneous injection at
3 days post-orthotopic tumor implantation for four
weeks. Control animals were treated with water. The
whole experiment was performed in three batches with
six, four and ten animals in control group to a total of
20 mice and seven, four and ten animals in CTCE-9908
group to a total of 21 mice. Four weeks post tumor implantation, caliper measurements were made to determine the orthotpic prostate tumor volume by measuring
perpendicular minor dimension (W) and major dimension (L) and volume was calculated by the W2 × L × 1/2
formula. Whole body fluorescence measurements were
made using Leica stereo fluorescence microscope (model
LZ12) equipped with ST-133 Micromax high speed CCD
camera (Princeton Instruments, Trenton, NJ) with anesthetized intact animals to determine total tumor burden
including metastases. Starting two weeks after implantation whole body imaging was performed once a week.
At the end of the study (four weeks) animals were euthanized and an open imaging was conducted to accurately
document and quantitate tumor burden (primary tumors
and metastatic tumor). Signals from individual organ
metastasis were quantitated from control animals and
CTCE-9908 treated animals.
Immunohistochemistry

Prostate tumors and lymph node metastases were paraffin embedded, and 4 μm thick sections were cut using
microtome. Tissue sections were immunostained with
anti-cytokeratin antibody, anti-Ki-67 antibody and antiCD34 antibody. Vectastain Elite ABC kit was used to
stain secondary antibody, and DAB chromagen was used
to develop color. Images were captured with Axiovision
software. For determining angiogenesis clusters of CD34
positive vessels (hot spots) were counted in 400× field in
tumors and lymph node metastasis.
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Statistical analysis

In vitro studies, statistical significance was determined
by Student t-test and non-parametric ANOVA test,
while in vivo assays were analyzed by Student t-test
using GraphPad Prism software version 3.0 (GraphPad,
San Diego, CA). p ≤0.05 was considered to be statistically significant.

expected, CXCL12 induced chemoinvasion of PC-3 cells;
treatment with 50 μg/ml CTCE-9908 significantly reduced CXCL12-induced chemoinvasion of PC-3 cells
(Figure 2). These results suggest that CTCE-9908 compound inhibits the CXCL12/CXCR4 axis and subsequent
chemoinvasion of PC-3 cells.
CXCL12/CXCR4 inhibition by CTCE-9908 leads to
inhibition of total tumor burden

Results
CXCR4 inhibition by CTCE-9908 does not inhibit cell
proliferation

In an effort to determine the effect of CTCE-9908 on
proliferation, PC-3 and C4-2B cells were treated with increasing concentrations of CTCE-9908 ranging from
10 ng/ml to 100 μg/ml for 24 to 72 hours. CTCE-9908
treatment did not significantly affect the PC-3 cell proliferation (Figure 1). Similar trend was observed with C42B cells up to 48 treatment of CTCE-9908, but at 72
hours a modest inhibition of growth observed at higher
concentrations of CTCE-9908.
CTCE-9908 inhibits CXCL12-induced cell invasion

Our previous reports demonstrate that CXCL12/CXCR4
activation induces protease expression and chemoinvasion of PC-3 cells. Herein, the effect of CTCE-9908 on
CXCL12-induced chemoinvasion was tested in PC-3
cells as the drug have no growth inhibitory effect. As

To determine the efficacy of CTCE-9908 in inhibiting
CXCL12/CXCR4-mediated tumor cell growth and dissemination, an orthotopic model of prostate cancer metastasis was utilized. GFP-transfected PC-3 tumor cells
were implanted into the ventral lobes of murine prostate. GFP stable transfection did not affect CXCR4 expression (data not shown). Mice were treated with a
daily dose of 25 mg CTCE-9908/kg mouse body weight
for four weeks. Caliper measurements of tumor volume
at the end of four weeks show a decrease in mean tumor
volume in CTCE-9908 treated animals (Figure 3B), although this decrease was not statistically significant.
Proliferation index was determined in control and
CTCE-9908 treated prostate tumors by immunostaining
tumor sections for Ki-67 expression. There is no significant difference present between Ki-67 positive tumor
cells between these groups suggesting that proliferation
rate of tumor cells was not affected by the CTCE-9908

PC-3 cells

Flourescence 530 nM

24 hours

48 hours

72 hours

C4-2B cells

24 hours

48 hours

72 hours

Figure 1 PC-3 cell proliferation in the presence of CTCE-9908. PC-3 and C4-2B cells were treated with 0, 10, 100, 500 ng/ml, 1, 10, 50 and
100 μg/ml concentrations of CTCE-9908 for 24 to 72 hours, and viable cells were determined with CyQUANT® NF cell proliferation assay.
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Figure 2 PC-3 cell chemoinvasion in the presence of CTCE9908. Chemonivasion of PC-3 cells were performed with Matrigelcoated inserts. PC-3 cells were pretreated with 1 and 50 μg/ml of
CTCE-9908 for 48 hours then seeded in chemoinvasion inserts and
exposed to CTCE-9908. 200 ng/ml of CXCL12 was added to the
lower chamber as a chemoattractant. Invaded cells at the bottom of
the filter were quantitated and shown in figure.
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(Additional file 1: Figure S1). The reduction in tumor
growth may be due to increased necrosis of tumor cells
as evidenced by low cytokeratin staining in CTCE-9908
treated mice (Additional file 2: Figure S2) which resulted
in shrinkage of tumor.
CTCE-9908 treatment significantly reduced lymph
node metastasis and distant metastases in orthotopic
mouse model (Figure 3A), however significant reduction
in primary tumor burden was not evident (Figure 3B).
Total body fluorescence measurements show that
CTCE-9908 treatment significantly inhibited total metastatic burden in mice (Figure 3C). Quantitation of sitespecific metastases show that lymph node metastases
were reduced by 40%, spleen metastasis by 75%, liver
metastasis by 93%, and 95% reduction in distant metastases in CTCE-9908 treated mice (data not shown).
Taken together, these data demonstrate that CTCE-9908
administration significantly inhibited dissemination of
cancer cells to various sites in the mouse.
CTCE-9908 inhibits angiogenesis in prostate tumor tissues

Primary tumor tissue from control and CTCE-9908treated mice were stained with anti-CD34 antibody to
determine the effect of CTCE-9908 on tumor angiogenesis. As shown by immunohistochemistry, CTCE-9908

A

B

C

Figure 3 CTCE-9908 intervention studies with PC-3 orthotropic prostate tumors. PC-3 tumors were grown in mouse prostate through
orthotropic implantation. 25 mg/kg of CTCE-9908 was administered to the mice. A) Whole body GFP fluorescence image of mice. B) Prostate
tumor volume was measured by calipers. C) Total GFP fluorescence of mice.
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treated tumors have fewer vessels, and these vessels are
also smaller in size (Figure 4A). Quantitation of microvessel density in the hot spots of angiogenesis show a
reduced CD34-positive vessel density in CTCE-9908
treated tumors (Figure 4B). Moreover, quantitation of
CD34 positive vessel density in lymph node metastatic
tissue shows a decrease in number in CTCE-9908
treated tumors (Additional file 3: Figure S3). These data
suggest that CTCE-9908 treatment inhibited the angiogenesis of primary and lymph node metastatic tumors.
The CTCE-9908-mediated inhibition of primary tumor
angiogenesis lead to inhibition of metastasis.

Discussion
Previous studies demonstrate that tumor cells are capable of usurping immune cell chemoinvasive pathways
for metastasis to secondary sites. Chemokines and chemokine receptors mediate physiological movement of
immune cells in the body. Among the family of chemokine and chemokine receptors mediating tumor cell invasion and metastasis, CXCL12/CXCR4 has gained a
central role in different types of tumors in mediating
tumor growth, angiogenesis and metastasis. In prostate
cancer cells, CXCL12 and CXCR4 play a key role in invasion and metastasis, leading to development and expansion of osseous metastasis. In this study we assessed
the effect of inhibition of the CXCL12/CXCR4 pathway
by a novel CXCR4 antagonist, CTCE-9908 on in vitro
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cell proliferation and invasion, and in vivo orthotopic
tumor growth, metastasis, and angiogenesis of PC cells.
Previous studies report that CTCE-9908 compound
inhibited cell proliferation in PC-3 cells at higher concentrations with no effect at lower concentrations [22]; our
data is in line with these studies, as CTCE-9908 compound
did not show significant inhibition in cell proliferation at
100 μM (which corresponds to 44 nM) concentration. This
lack of inhibitory effect on PC-3 cells can be attributed to
the fact that cultured PC-3 cells express low or no CXCL12
[5], and therefore CXCR4 activation could be low in these
cells. Previous report by Provasnik et al. support this observation that CTCE-9908 administration do not inhibit the
subcutaneous tumor growth [22]. As opposed to cultured
cancer cells, in vivo bone tumors express CXCL12 in prostate cancer cells in addition to osteoblasts and endothelial
cells. Primary tumors also express CXCL12 in epithelial
cells. The CXCL12/CXCR4 axis has been shown to promote cell survival by inhibiting apoptosis in cancer cells;
thus, CTCE-9908-mediated inhibition of the CXCL12/
CXCR4 pathway leads to loss of protection from apoptosis
and increased cell death. Our data support this notion, as
CTCE-9908-treated tumors showed enhanced necrotic
areas, suggesting that loss of the CXCL12/CXCR4 axis mediated cell survival leading to enhanced necrosis in tumor
cells. But, we cannot rule out the role of growth inhibition
of CTCE-9908 in our model as mean tumor growth is
inhibited in CTCE-9908 treated group, though the data did
not reach statistical significance.

A

B

Figure 4 Microvessel density in CTCE-9908-treated PC-3 tumors. A) Prostate tumor tissues were stained with anti-CD 34 antibody.
B) Quantitation of CD34+ vessels in control and CTCE-9908 treated prostate tumor tissue. *Represents statistically significant, where p = 0.0021.
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We have previously shown that the CXCL12/CXCR4 axis
in PC-3 cells induce MMP-9 expression via activation of
PI3K and MAPK pathways, and this activation mediates
in vitro cell invasion of PC-3 cells [24]. Bone colonizing
PC-3 cells induce the expression of active MMP-9 at earlier
time periods suggesting that CXCL12/CXCR4-mediated
homing of PC cells to bone would functionally link with
the expression of MMP-9 in local bone tumor microenvironment and induce invasive bone tumor growth [5]. To
determine whether CTCE-9908 compound could inhibit
invasion of PC-3 cells, we used the lower concentration of
50 μg/ml in cell invasion studies. Although this concentration of CTCE-9908 did not inhibit cell proliferation, our
data suggest that 50 μg/ml CTCE-9908 potently inhibited
the CXCL12-induced PC-3 cell invasion. To determine
whether inhibition of invasion could translate into inhibition of metastasis formation, we treated mice implanted
with orthotopic tumors with CTCE-9908. The whole body
quantitation of fluorescence measurements shows that
CTCE-9908 treatment significantly reduced total tumor
burden as a measure of total body fluorescence. To our
knowledge, this is the first report to document that targeting the CXCL12/CXCR4 axis through CTCE-9908 inhibited the metastatic burden in an orthotopic prostate cancer
model system. Both lymph node and distant metastases
were significantly inhibited in CTCE-9908 treated tumors,
but distant metastases were strongly inhibited compared to
lymph node metastases. Similar observations were found
with CTCE-9908 in a breast cancer model where total
metastatic burden was significantly inhibited upon CTCE9908 administration [25]. CXCL12/CXCR4 mediated invasive function has implications in clinical management of
patients as chemotherapy resistant tumors cells often express high levels of CXCR4 [26] and this may lead to the
development of metastases in these patients via CXCL12/
CXCR4 activation. In addtion, prostate cancer progenitor
cells express CXCR4 [27] and often these cells are resistant
to current chemo and radiation therapy practices, thus,
combination therapy with anti-CXCR4 strategies consisting
of CTCE-9908 may prevent the further spread of tumor in
patients.
Tumor angiogenesis plays a key role in tumor growth
and development of metastases. CXCL12/CXCR4 signaling
has been shown to modulate the expression of angiogenic
cytokines/chemokines in prostate cancer cells [28]. Expression of these proangiogenic factors can recruit endothelial
precursor cells to the tumor sites to facilitate angiogenesis.
To determine the effect of CXCR4 inhibition on tumor
angiogenesis we measured hotspots of angiogenesis in primary and lymph node metastatic tumor tissues for CD34
positive blood vessels. CTCE-9908 treatment significantly
inhibited angiogenesis in both primary and lymph node
metastases. Porvasnik et al. reported that CTCE-9908 treatment reduced tumor angiogenesis by down regulating
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VEGF production and myeloid derived suppressor cell
(CD11b positive) recruitment into tumor tissues [22].
CD11b cells have been recently shown to express CXCR4
and migrate towards the CXCL12 expressing cells.
Our studies show that CTCE-9908 is efficacious in inhibiting total tumor burden without significantly reducing
primary tumor burden suggesting that targeting CXCL12/
CXCR4 axis may be therapeutically beneficial for the management of prostate cancer patients undergoing chemo or
radiation therapy.

Conclusions
The data presented in the study demonstrate that
CTCE-9908 is efficacious in preventing spread of tumor
cells from primary site by inhibiting invasive and angiogenic functions of CXCL12/CXCR4 axis in primary
tumor environment.
Additional files
Additional file 1: Figure S1. A) Immunohistochemical analysis of Ki-67
in PC-3 tumors. Control and CTCE-9908 treated prostate tumor tissues
were stained for Ki-67 antigen. B) Quantitation of total Ki-67 positive cells
in control and treated group. Statistical difference between groups is not
significant, where p = 0.0897.
Additional file 2: Figure S2. Immunohistochemical analysis of
cytokeratin in PC3 tumors. Control and CTCE-9908 treated prostate
tumor tissues were stained for cytokeratin. Arrow represents low staining
necrotic area.
Additional file 3: Figure S3. CD34 staining of lymph node metastasis
in control (left) and CTCE-9908 treated mice (right). A representative hot
spot of CD34+ vessels is shown. Graphical representation of microvessel
densities between control and treated groups of metastatic tumor
sections. *represents statistically significant, where p = 0.0296.
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